HANG LEI: Open Payments
NPI 1396412631 · BRISTOL, TN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,504 in 82 payments from 10 companies in 2025. Trend: 2023 $654 · 2024 $455 · 2025 $1,504
Food & beverage: $1,504
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 21 | $348 |
| Alkermes, Inc. | 12 | $271 |
| Janssen Pharmaceuticals, Inc | 13 | $190 |
| Teva Pharmaceuticals USA, Inc. | 8 | $185 |
| Lundbeck LLC | 10 | $141 |
| E.R. Squibb & Sons, L.L.C. | 7 | $139 |
| Vanda Pharmaceuticals Inc. | 5 | $101 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $79 |
| ABBVIE INC. | 2 | $31 |
| Otsuka America Pharmaceutical, Inc. | 1 | $20 |
Products named: INGREZZA, ARISTADA, INVEGA SUSTENNA, COBENFY, UZEDY, REXULTI, HETLIOZ, LYBALVI.
Industry payments across TN — which companies pay providers there.
